Both terbinafine and ketoconazole plasma concentration, and their residual contents in toenails will be measured with a validated LC/MS‐MS method.

Secondary Outcome Measures:

(1) Efficacy is evaluated 24 weeks after the start of treatment and will be recorded at baseline, 8-week, 16-week and 24-week. [ Time Frame: baseline, 8-week, 16-week and 24-week ] [ Designated as safety issue: Yes ]

The degrees of improvement are assessed based on each toenail as follows:

Complete cure is defined as regeneration of a healthy nail plate to replace the diseased nail.

Marked improvement is defined as regeneration of a healthy nail plate in at least 70% of the affected nail.

Improvement is defined as regeneration in 40-70% of the affected nail.

Slight improvement is defined as regeneration in less than 40%.

No change is defined as the absence of change or exacerbation of the disease condition or the side effect.

A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.

Experimental: 6% terbinafine patch

A 10‐cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole

Drug: 6 mg terbinafine and 2 mg ketoconazole containing patch

A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.

Experimental: 8% terbinafine patch

A 10‐cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole

Drug: 8 mg terbinafine and 2 mg ketoconazole containing patch

A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.

Detailed Description:

This study is to explore the optimization of anti‐onychomycosis patch with various formulation contents (three patch groups: 3%, 6% and 8% of terbinafine (contains 3‐mg, 6‐mg and 8‐mg/patch terbinafine, respectively) combined with fixed 2% ketoconazole (contains 2‐mg ketoconazole/patch) and its safety profile. At least 18 patients (age: 20 to 75 years old) with one or two feet toenails infected simultaneously need to complete the whole study. Patients will be assigned to one of patch groups. The patients with only one infected toenail will also apply one patch on other foot with uninfected toenail. The patch will be applied on the foot on the dorsal site and leave it there for two consecutive days. Totally six patches will be used for each week. The duration of therapy will be 24 weeks. The patients' blood sample and toenail clippings will be collected every 8 weeks and will be analyzed as well as the safety profiles. The most appropriate patch formulation will be selected on the drug content residues in toenail. The safety profile will be also presented and discussed with various anti‐onychomycosis patch formulations.

Eligibility

Ages Eligible for Study:

25 Years to 75 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Male and females 20‐75 years of age

Fungal infection of one or both toenails will be confirmed using the method of histopathological examination with periodic acid‐Schiff (PAS) staining (Yang JH, et al., 2007)

The toenail infection can be due to a dermatophyte, yeast or mixed infections (dermatophyte and non‐dermatophyte)

The target toenail area must have at least 25% to no more than 75% disease involvement without spikes

Patients agree to sign the informed consent form

Exclusion Criteria:

Using any kind of systemic or topical nail lacquer solution antifungal drugs within 6 months before at screening visit; or using any other topical antifungal agents, such as ointment, cream, gel, solution, suspension, oil or lotion forms, within two weeks before at screening visits

Patients with the target toenail involving the matrix (lunula) or having less than 2 mm clear (unaffected) nail plate length beyond the proximal fold

Presence of dermatophytoma on the target nail

Using professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit

Patients who are unwilling to provide nail clippings

Patients who have been previously reported to be allergic to topical or systemic terbinafine or ketoconazole therapy or both

Known pregnancy or plan to get pregnant within study duration or lactation at time of enrollment

Unconsciousness or inability to understand this form or this study project.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01615913